Evidence mapPaperPMID 42415409Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2026

Catecholamines Activate a Tumour Progression Program in Differentiated Tumour Hepatocytes.

Elise Lelou, Claudine Rauch, Hélène Dubois-Pot-Schneider, Marjorie Dufresne, Abolfazl Zekri Yazdi, Maelle Guillout, Luis Cano, Lise Desquilles, Nicolas Nesseler, Marc Bourgeois and 5 more

Abstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Catecholamines Activate a Tumour Progression Program in Differentiated Tumour Hepatocytes.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elise LelouINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Claudine RauchINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Hélène Dubois-Pot-SchneiderUniversité de Lorraine, CNRS, CRAN, Nancy, France.
Marjorie DufresneINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Abolfazl Zekri YazdiINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Maelle GuilloutCore Facility H2P2, CNRS, INSERM, UMS Biosit, University of Rennes, Rennes, France.ORCID https://orcid.org/0009-0006-3033-7714
Luis CanoINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Lise DesquillesINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Nicolas NesselerINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Marc BourgeoisDepartment of Biochemistry, CHU Rennes, Pontchaillou University Hospital, Rennes, France.
Claude BendavidINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Julie MassartINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Orlando MussoINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Anne CorluINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.
Caroline AninatINSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), University of Rennes, Rennes, France.ORCID https://orcid.org/0000-0002-9008-0686

Funding

Cancéropôle Grand-Ouest and Région BretagneInstitut National Du Cancer INCA_12688Ligue Contre le Cancer
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe sympathetic nervous system is involved in the progression and aggressiveness of several cancers, including hepatocellular carcinoma (HCC). However, the specific effects of sympathetic innervation and catecholamines on tumour hepatocyte behaviour remain poorly understood. In this study, we aimed to investigate the role of sympathetic fibres and catecholamines in the progression of HCC.

methodsThe distribution of sympathetic nerves was mapped in 10 human HCC samples using multiplex immunofluorescence labeling. Adrenergic receptors (ADR) and enzymes involved in catecholamine degradation were assessed in three HCC (HepaRG, BC2, Huh-7) and one hepatoblastoma (HepG2) cell lines. The impact of catecholamines on gene and protein expression and metabolic pathways was assessed in differentiated HepaRG-hepatocytes, and the results were verified in primary human hepatocyte (PHH) cultures. The clinical relevance of the findings was evaluated in two transcriptomics datasets.

resultsAbundant and tortuous sympathetic fibres were detected in non-tumour liver tissues adjacent to the HCC invasion front. Differentiated HepaRG-hepatocytes expressed both α

conclusionsCatecholamines induce an aggressive phenotype in differentiated tumour hepatocytes localized at the invasive front, suggesting their involvement in cancer progression. Understanding the interplay between the sympathetic nervous system and HCC may offer novel therapeutic opportunities.

Indexed as

Carcinoma, HepatocellularCatecholaminesHepatocytesLiver NeoplasmsAdrenergic FibersCell DifferentiationCell Line, TumorCell ProliferationDisease ProgressionHumansSympathetic Nervous SystemCatecholaminesdifferentiated HepaRG‐hepatocytesepinephrinehepatocellular carcinomanorepinephrinesympathetic innervationα1A‐ and β2‐adrenoreceptors

Identifiers

PMID42415409
PMCPMC13342482

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.